WO2001005760A2 - New process for the preparation of spiro [(4-cyclohexanone)-[3h]indol]-2'[1'h]-one derivatives - Google Patents

New process for the preparation of spiro [(4-cyclohexanone)-[3h]indol]-2'[1'h]-one derivatives Download PDF

Info

Publication number
WO2001005760A2
WO2001005760A2 PCT/HU2000/000081 HU0000081W WO0105760A2 WO 2001005760 A2 WO2001005760 A2 WO 2001005760A2 HU 0000081 W HU0000081 W HU 0000081W WO 0105760 A2 WO0105760 A2 WO 0105760A2
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
protective group
compound
stands
defined above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2000/000081
Other languages
French (fr)
Other versions
WO2001005760A3 (en
Inventor
Csaba GÖNCZI
Éva CSIKÓS
István HERMECZ
Gergely HÉJA
Árpád ILLÁR
Lajos Nagy
Andrea SÁNTÁNÉ CSUTOR
Attila Simon
Kálmán SIMON
Ágota SMELKÓNÉ ESEK
Tiborné SZOMOR
Györgyné SZVOBODA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200030136T priority Critical patent/SI1200404T1/en
Priority to JP2001511421A priority patent/JP2003505371A/en
Priority to BRPI0012473-7A priority patent/BR0012473B1/en
Priority to SK48-2002A priority patent/SK286875B6/en
Priority to US10/030,648 priority patent/US6573386B1/en
Priority to HR20020143A priority patent/HRP20020143B1/en
Priority to MXPA01013341A priority patent/MXPA01013341A/en
Priority to PL352477A priority patent/PL198521B1/en
Priority to CA002378201A priority patent/CA2378201C/en
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to DE60002472T priority patent/DE60002472T2/en
Priority to AT00949825T priority patent/ATE238989T1/en
Priority to AU63084/00A priority patent/AU6308400A/en
Priority to EP00949825A priority patent/EP1200404B1/en
Publication of WO2001005760A2 publication Critical patent/WO2001005760A2/en
Publication of WO2001005760A3 publication Critical patent/WO2001005760A3/en
Anticipated expiration legal-status Critical
Priority to US10/409,488 priority patent/US6884895B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • Spiro[(4-cyclohexanone)-[3H]indol-2'[ H]-one and dispiro[(l,3-dioxolan)-2,4'- cyclohexane-[3H]indol]-2"[l"H]-one derivatives are important intermediates to the vasopressine V 2 antagonistic compound, SR 121463.
  • the dispiro[(l,3- dioxolan)-2,4'-cyclohexane-l ,3"-(5"-ethoxy)-[3H]indol]-2"[l"H]-one (compound of formula VII) can be prepared by reacting 4-ethoxyphenylhydrazine with 4-(l,3-dioxolan)cyclohexane-carboxylate sodium salt followed by cyclization of the resulting l-(4'-ethoxyphenyl)-2-(4"-/1.3- dioxolan/-cyclohexane-carbonyl)-hydrazine.
  • the compound of formula VII is obtained by oxidation of the spiro[(4-hydroxy-cyclohexane)-l,3 '(5'-ethoxy)- [3H]indol-2'[l 'H]-one to the appropriate cyclohexanone derivative, from which the ketale of the formula VII is prepared by reaction with ethylene glycol.
  • the subject of our invention is a process for the preparation of spiro[(4- cyclohexanone)-[3H]indol]-2' [l 'H]-one derivatives of the general formula I
  • R and R independently stand for hydrogen, C ⁇ -4 alkyl, C alkoxy,
  • reaction of the compound of general formula II - wherein R and R are as defined above - with the compound capable to introduce a protective group is preferably carried out in the presence of a catalyst, preferably in the presence of p- toluenesulfonic acid.
  • a catalyst preferably in the presence of p- toluenesulfonic acid.
  • solvent halogenated hydrocarbons preferably dichloromethane can be used.
  • Cyclization of the compounds of general formula IV is carried out in the presence of an alkali alcoholate, preferably in the presence of sodium ethylate, potassium t- butylate.
  • acryilic acid(C ⁇ - )ester for protective group, the process can advantageously performed as a "one pot " method, in a polar solvent, in the presence of a base.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to a process for the preparation of spiro[(4-cyclohexanone)- [3H]indol]- 2'[1'H]- one derivatives of general formula (I) - wherein R?1 and R2¿ independently stand for hydrogen, C¿1-4?alkyl, C1-4alkoxy, C1-4alkylthio, C1-4 polyfluoroalkyl, C1-4 polyfluoroalkoxy, C3-7 cycloalkyloxy, C3-7cycloalkylthio, phenoxy, benzyloxy or nitro group -, characterized by reacting an indolin-2-one derivative of general formula (II) - wherein R?1 and R2¿ are as defined above - with a compound capable for introducing a protective group, coupling the compound of general formula (III), thus obtained - wherein R?1 and R2¿ are as defined above and A stands for a protective group - with acrylic acid C¿1-4?ester, cyclizing the resulting compound of general formula (IV)- wherein R?1 and R2¿ are as defined above - with a compound capable for introducing a protective group, coupling the compound of formula (III) thus obtained, - wherein R?1 and R2¿ are as defined above and A stands for a protective group - with an acrylic acid C1-4 ester; cyclizing the resulting compound of formula (IV) - wherein R?1 and R2¿ are as defined above R3 stands for C¿1-4?alkyl and A stands for a protective group -, eliminating the -COOR?3¿ group and the A protective group of the keto-ester of general formula (V) - wherein R?1 and R2¿ are as defined above, R3 stands for C¿1-4?alkyl and A stands for a protective group -, optionally without isolation of the compounds of general formulae (IV) and/or (V) and/or (VI).

Description

New process for the preparation of spiro[(4-cyclohexanone)-[3H]indol-
2'[l'H]-one derivatives
Spiro[(4-cyclohexanone)-[3H]indol-2'[ H]-one and dispiro[(l,3-dioxolan)-2,4'- cyclohexane-[3H]indol]-2"[l"H]-one derivatives are important intermediates to the vasopressine V2 antagonistic compound, SR 121463.
For example, as described in patent application WO 9715556 the dispiro[(l,3- dioxolan)-2,4'-cyclohexane-l ,3"-(5"-ethoxy)-[3H]indol]-2"[l"H]-one (compound of formula VII) can be prepared by reacting 4-ethoxyphenylhydrazine with 4-(l,3-dioxolan)cyclohexane-carboxylate sodium salt followed by cyclization of the resulting l-(4'-ethoxyphenyl)-2-(4"-/1.3- dioxolan/-cyclohexane-carbonyl)-hydrazine.
According to another synthetic route (EP 636608) the compound of formula VII is obtained by oxidation of the spiro[(4-hydroxy-cyclohexane)-l,3 '(5'-ethoxy)- [3H]indol-2'[l 'H]-one to the appropriate cyclohexanone derivative, from which the ketale of the formula VII is prepared by reaction with ethylene glycol.
Disadvantages of both of the above syntheses are the toxic starting materials, many- step syntheses, low yields of some synthetic steps, expensive reagents and extreme reaction conditions in certain reactions.
To our surprise, we have found that in contrast to the analogous reaction described in the literature (Annalen 1941, 548, 1 17-146; J. Am. Chem. Soc. 1953, 75, 5301- 5305; J. Chem. Soc. C, 1970, 796-800, J. Med. Chem. 1993, 36, 2459-2469) the addition of methyl or ethyl acrylate to 5-ethoxy-indolinone, followed by Dieckmann-condensation, hydrolysis and decarboxylation does not lead to a homogeneous product, that is why the procedures described in the literature above are not suitable for industrial synthesis. We have found that the hydrogen in position-2 of the 5-ethoxy-indolinone has to be substituted by a protective group, if we want the subsequent reactions to proceed in the desired direction. The subject of our invention is a process for the preparation of spiro[(4- cyclohexanone)-[3H]indol]-2' [l 'H]-one derivatives of the general formula I
- wherein R and R independently stand for hydrogen, Cι-4alkyl, C alkoxy,
Cι-4alkylthio, C^polyfiuoroalkyl, C1-4polyfluoroalkoxy, C3-7cycloalkyloxy, C3-7cycloalkylthio, phenoxy, benzyloxy or nitro group -, characterized by reacting an indolin-2-one derivative of the general formula II - wherein R1 and R2 are as defined above - with a compound capable for introducing a protective group, coupling the compound of formula III thus obtained, - wherein R1 and R" are as defined above and A stands for a protective group - with an acrylic acid Chester, cyclizing the resulting compound of the formula IV - wherein R and R are as defined above, R J stands for C)-4 alkyl and A stands for a protective group -, eliminating the -COORJ group and the A protective group of the keto-ester of general formula V - wherein R1 and R2 are as defined above, RJ stands for C1-4 alkyl and A stands for a protective group-, optionally without isolation of the compounds of the general formulae IV and/or V and/or VI (see "Figures 1 and 2"). As for compounds capable to introduce a protective group, preferably 2,3- dihydropyrane, triethyl orthoformate or an acrylic acid (Cι-4)ester can be applied.
1 9
The reaction of the compound of general formula II - wherein R and R are as defined above - with the compound capable to introduce a protective group is preferably carried out in the presence of a catalyst, preferably in the presence of p- toluenesulfonic acid. As for solvent halogenated hydrocarbons, preferably dichloromethane can be used.
The reaction of the compounds of general formulae II or III - wherein R , R~ and A are as defined above - with the acrylic acid (C )ester is carried out in the presence of a catalyst, preferably in the presence of an alkali alcoholate, favorably sodium alcoholate. •->
Cyclization of the compounds of general formula IV is carried out in the presence of an alkali alcoholate, preferably in the presence of sodium ethylate, potassium t- butylate.
Using acryilic acid(Cι- )ester for protective group, the process can advantageously performed as a "one pot" method, in a polar solvent, in the presence of a base.
Compounds of the general formulae III, IV, V and VI - wherein R1. R2. R" and A are as defined above - are new compounds.
Further details of the invention are demonstrated by the following examples, without limiting the claims to the examples.
Examples
1./ To 38.33 g of 5-ethoxy-indan-2-one 2.12 g of p-toluenesulfonic acid and 880 ml of dichloromethane are added, then under stirring 59 ml of dihydropyrane. The reaction mixture is stirred until complete dissolution (approx. 2 hours), then it is allowed to stand for 36 hours. The resulting brown solution is washed with 8 % aqueous sodium hydrogencarbonate solution, dried over sodium sulfate and evaporated. The residue is slowly poured into 500 ml of petroleum ether. The resulting precipitate is filtered off, washed with a small amount of petroleum ether. Thus, 42.4 g of l-(2-tetrahydropyranyl)-5-ethoxy-indolin-2-one is obtained, mp.: 108 - 1 10 °C. Yield: 75%
To 41.8 g of l-(2-tetrahydropyranyl)-5-ethoxy-indolin-2-one. 1.2 g of sodium ethylate and 440 ml of toluene are added. To the resulting solution 34 ml of ethyl acrylate is added slowly, under stirring, at 25 °C, in a period of 4 hours. The reaction mixture is stirred for additional 2 hours, then it is washed with 8 % aqueous sodium hydrogencarbonate solution, dried over sodium sulfate. clarified with active carbon, filtered and concentrated in vacuo.
The residue is slowly poured into 250 ml of petroleum ether. The resulting solid material is filtered off, washed with petroleum ether. 58 g of l-(2- tetrahydropyranyl)-3-(di-/ethoxycarbonylethyl/)-5-ethoxy-indolin-2-one is obtained. mp.: 84 - 86 °C. Yield: 78%.
178 g of l-(2-tetrahydropyranyl)-3-(di-/ethoxycarbonylethyl/)-5-ethoxy-indolin-2- one in 1300 ml of toluene is stirred with 60.4 g of sodium ethylate and 6 g of tetrabutylammonium bromide at 55 °C for 3,5 hours. After cooling the reaction mixture is extracted consecutively with 300 ml of ice-cold water. 300 ml of 1 N hydrochloric acid, and 150 ml of water, clarified with active carbon and Fuller's earth, and filtered. The filtrate is evaporated in vacuo, the residue is heated under stirring at reflux temperature for 3.5 hours in the mixture of 790 ml of 50 %- ethanol and 315 ml cone, hydrochloric acid. The mixture is then poured into 3000 ml of water, the aqueous phase is extracted with 2x600 ml and 3x300 ml of toluene, dried over sodium sulfate, evaporated in vacuum. The residue is crystallized in diisopropyl ether. The resulting material is filtered off, washed with diisopropyl ether. Thus 60.1 g of spiro[(4-cyclohexanone)-l,3 '(5'-ethoxy)-[3H]indol-2'[ H]-one is obtained, mp.:
171 - 172 °C. Yield: 60 %.
2.1 Into 318 ml of dimethyl sulfoxide 112.7 g of 5-ethoxy-indan-2-one is added, then, under stirring, 3.82 g of potassium /-butylate. To that suspension, after 10 minutes of stirring, 172.1 g of methyl acrylate is added, dropwise. at a temperature of 40 - 45 °C. in a period of 70 minutes. The mixture is stirred at that temperature for additional 65 minutes, then to it is added 161 g of potassium -butylate, in a period of 30 minutes, while keeping the temperature below 60 °C. The t-butanol is distilled off, the thick residue is poured into 1780 ml of water, the solution is clarified with active carbon and filtered. The filtrate is stirred in a 85 °C bath. When it reaches the 68 °C (approx. 25 min.) it is seeded, then stirring is continued for additional 3 hours, at a temperature of max. 81 °C. The mixture is then cooled to room temperature, the resulting precipitate is filtered off and washed thoroughly with water. Thus, 1 10.7 g of spiro[(4-cyclohexanone)- 1.3 '(5'-ethoxy)-[3H]indol- 2'[ l *H]-one is obtained, mp.: 184 - 186 °C, it suitable for the next step. Yield: 67 %.
3.1 1 1.2 g of 5-ethoxy-indan-2-one and 220 ml of triethyl orthoformate are stirred at 135-140° C for 20 hours, then the reaction mixture is evaporated in vacuo. 17.2 g of l-(diethoxy-methylene)-5-ethoxy-indolin-2-one is obtained as an oil. Its structure was proved by NMR spectroscopy. Yield: 92 %.
To the mixture of 17.2 g of l-(diethoxy-methylene)-5-ethoxy-indolin-2-one, 1.5 g of potassium t-butylate and 170 ml of toluene 12.6 ml of ethyl acrylate is added dropwise, at 20 - 30°C, in a period of 1 hour. After additional 90 minutes of stirring 50 ml of water is added to the reaction mixture, the phases are separated, the organic phase is washed with water, dried over sodium sulfate, evaporated in vacuum. 22.2 g of l-(diethoxy-methylene)-3-(di-/ethoxycarbonylethyl/)-5-ethoxy- indolin-2-one is obtained in the form of yellow-brown crystallizing oil, which is crystallized from 110 ml of n-hexane. 15.1 g crystalline product is obtained, mp:
82-83°C. Yield: 62 %.
15 g of l-(diethoxy-methylene)-3-(di-/ethoxycarbonylethyl/)-5-ethoxy-indolin-2- one is dissolved in 150 ml of toluene, and to the solution 7.2 g of potassiuπ - butylate is added under stirring, in 10 minutes. The reaction mixture is stirred at room temperature for 2 hours, then water is added to it. the phases are separated, the organic phase is washed with water, dried over sodium sulfate. evaporated in vacuum. Thus, 10.2 g of spiro[(3-ethoxycarbonyl-4-cyclohexanon)-1.3 '(r- diethoxy-methylene-5"-ethoxy)-[3H]indol]-2'-one is obtained in the form of a brown oil, its structure was proved by NMR spectroscopy. Yield: 76 %.
4,05 g of spiro[(3-ethoxycarbonyl-4-cyclohexanon)- 1.3 '( l '-diethoxy-methylene-5*- ethoxy)-[3H]indol-2'-one is stirred for 2 hours at room temperature in the mixture of 20 ml of 96 % ethanol and 0,5 ml of 2N hydrochloric acid, the reaction mixture is then cooled with ice-water to 5°C. The precipitating spiro[(3-ethoxycarbonyl-4- cyclohexanon)-l,3 '( -formyl-5 '-ethoxy)-[3H]indol]-2'-one is filtered off, mp.: 133 - 136 °C. Yield: 52 %.
5 g of spiro[(3-ethoxycarbonyl-4-cyclohexanon)-l,3 ,( r-formyl-5 '-ethoxy)- [3H]indol]-2'-one is dissolved in 100 ml of acetic acid, 25 ml of 5N sulfuric acid is added to it. The mixture is refluxed under stirring, then it is evaporated in vacuum. To the residue water is added, the pΗ is adjusted to pΗ 7 with sodium hydroxide solution. 3.1 g of solidifying oil precipitates is obtained, which is identical with the spiro[(4-cyclohexanon)-l,3 '(5'-ethoxy)-[3H]indol]-2'[ H]-one obtained by another route. Mp.: 139 - 140° C. Yield: 86 %.

Claims

Claims
I .) Process for the preparation of spiro[(4-cyclohexanone)-[3H]indol]-2' [l 'H]- one derivatives of the general formula I
1 7 - wherein R and R independently stand for hydrogen, C1-4alkyl, C alkoxy, Ci. 4alkylthio, Cι.4polyfluoroalkyl, Cι-4polyfluoroalkoxy, C3.7cycloalkyloxy, C3-7cycloalkylthio, phenoxy, benzyloxy or nitro group -, characterized by reacting an indolin-2-one derivative of the general formula II - ι wherein R and R" are as defined above - with a compound capable for introducing a protective group, coupling the compound of general formula III, thus obtained -
1 7 wherein R and R are as defined above and A stands for a protective group - with acrylic acid Chester, cyclizing the resulting compound of the general formula IV -
1 7 wherein R and R- are as defined above - with a compound capable for introducing a protective group, coupling the compound of formula III thus obtained, - wherein
1 7 R and R are as defined above and A stands for a protective group - with an acrylic acid Cι-4ester; cyclizing the resulting compound of the formula IV - wherein R1
7 ^ and R are as defined above, R stands for C!- alkyl and A stands for a protective group -, eliminating the -COOR group and the A protective group of the keto-ester
1 "" of general formula V - wherein R and R~ are as defined above. RJ stands for C]- alkyl and A stands for a protective group-, optionally without isolation of the compounds of the general formulae IV and/or V and/or VI.
2.) Process according to claim 1.) characterized by using 2,3-dihydropyrane, triethyl orthoformate or acrylic acid C)-4ester as a compound capable for introducing a protective group.
3.) Process according to claims 1-2., characterized by carrying out the reaction of the compound of the general formula II - wherein R1 and R2 are as defined in claim 1.-, with the compound capable for introducing a protective group in the presence of a catalyst.
4.) Process according to claim 1., characterized by carrying out the reaction of the compounds of the general formula II or III - wherein R1, R2 and A are as defined in claim 1 - with an acrylic acid C1-4ester in the presence of a catalyst.
5.) Process according to claims 3-4., characterized by using as catalyst an acidic or alkaline catalyst, preferably p-toluenesulfonic acid or alkali alcoholate.
1 7
6.) Compound of the general formula III, wherein R , R" and A are as defined in claim 1.
7.) Compound of the general formula IV, wherein R , R", RJ and A are as defined in claim 1.
8.) Compound of the general formula V, wherein R , R , RJ and A are as defined in claim 1.
9.) Compounds of the general formula VI , wherein R1, R~ and RJ are as defined in claim 1.
PCT/HU2000/000081 1999-07-15 2000-07-13 New process for the preparation of spiro [(4-cyclohexanone)-[3h]indol]-2'[1'h]-one derivatives Ceased WO2001005760A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA002378201A CA2378201C (en) 1999-07-15 2000-07-13 New process for the preparation of spiro[(4-cyclohexanone)-[3h]indol]-2'[1'h]-one derivatives
BRPI0012473-7A BR0012473B1 (en) 1999-07-15 2000-07-13 process for the preparation of spiro [(4-cyclohexanone) - [3h] indol-2 '[1'h] -one derivatives
DE60002472T DE60002472T2 (en) 1999-07-15 2000-07-13 PROCESS FOR PREPARING SPIRO ((4-CYCLOHEXANONE) - (3H) INDOL) -2 '(1'H) -ONE DERIVATIVES
US10/030,648 US6573386B1 (en) 1999-07-15 2000-07-13 Process for the preparation of spiro[(4-cyclohexanone)-[3H]indol]-2′[1′H]-one derivatives
HR20020143A HRP20020143B1 (en) 1999-07-15 2000-07-13 Ðew process for the preparation of spiro [(4-cyclohexanone)-[3h]indol-2'[1'h]-one derivatives
MXPA01013341A MXPA01013341A (en) 1999-07-15 2000-07-13 New process for the preparation of spiro [(4-cyclohexanone)-[3h]indol]-2'[1'h.
PL352477A PL198521B1 (en) 1999-07-15 2000-07-13 Novel method of obtaining derivatives of spiro [(4-cyclohexanon)-[3h]indole0-2'[1'h]-one
SI200030136T SI1200404T1 (en) 1999-07-15 2000-07-13 Process for the preparation of spiro((4-cyclohexanone)- (3h) indol-2'(1'h)-one derivatives
SK48-2002A SK286875B6 (en) 1999-07-15 2000-07-13 Process for preparation of spiro[(4-cyclohexanone)-[3H]indol]- 2'[1'H]-one derivatives
JP2001511421A JP2003505371A (en) 1999-07-15 2000-07-13 Novel method for producing spiro [(4-cyclohexanone)-[3H] indole] -2 '[1'H] -one derivative
AT00949825T ATE238989T1 (en) 1999-07-15 2000-07-13 METHOD FOR PRODUCING SPIRO((4-CYCLOHEXANONE)-(3H)INDOLE)-2'(1'H)-ONE DERIVATIVES
AU63084/00A AU6308400A (en) 1999-07-15 2000-07-13 New process for the preparation of spiro ((4-cyclohexanone)-(3h)indol)-2'(1'h)-one derivatives
EP00949825A EP1200404B1 (en) 1999-07-15 2000-07-13 Process for the preparation of spiro[(4-cyclohexanone)- [3h] indol-2'[1'h]-one derivatives
US10/409,488 US6884895B2 (en) 1999-07-15 2003-04-08 Process for the preparation of spiro[(4-cyclohexanone)-[3]indol]-2′[1′H]-one derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9902374 1999-07-15
HU9902374A HUP9902374A3 (en) 1999-07-15 1999-07-15 Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/030,648 A-371-Of-International US6573386B1 (en) 1999-07-15 2000-07-13 Process for the preparation of spiro[(4-cyclohexanone)-[3H]indol]-2′[1′H]-one derivatives
US10030648 A-371-Of-International 2000-07-13
US10/409,488 Division US6884895B2 (en) 1999-07-15 2003-04-08 Process for the preparation of spiro[(4-cyclohexanone)-[3]indol]-2′[1′H]-one derivatives

Publications (2)

Publication Number Publication Date
WO2001005760A2 true WO2001005760A2 (en) 2001-01-25
WO2001005760A3 WO2001005760A3 (en) 2001-07-19

Family

ID=89998733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2000/000081 Ceased WO2001005760A2 (en) 1999-07-15 2000-07-13 New process for the preparation of spiro [(4-cyclohexanone)-[3h]indol]-2'[1'h]-one derivatives

Country Status (17)

Country Link
US (2) US6573386B1 (en)
EP (1) EP1200404B1 (en)
JP (1) JP2003505371A (en)
CN (1) CN1149194C (en)
AT (1) ATE238989T1 (en)
AU (1) AU6308400A (en)
BR (1) BR0012473B1 (en)
CA (1) CA2378201C (en)
CZ (1) CZ2002147A3 (en)
DE (1) DE60002472T2 (en)
ES (1) ES2197106T3 (en)
HR (1) HRP20020143B1 (en)
HU (1) HUP9902374A3 (en)
MX (1) MXPA01013341A (en)
PL (1) PL198521B1 (en)
SK (1) SK286875B6 (en)
WO (1) WO2001005760A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638548B2 (en) * 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
HUE040133T2 (en) 2014-07-15 2019-02-28 Gruenenthal Gmbh Substituted azaspiro(4.5)decane derivatives
TW201607923A (en) 2014-07-15 2016-03-01 歌林達有限公司 Substituted azaspiro (4.5) decane derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3395156A (en) * 1965-08-16 1968-07-30 American Home Prod 1'-phenylspiro (cyclohexane-1, 3'-indoline)-2', 4-dione
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2740136B1 (en) 1995-10-24 1998-01-09 Sanofi Sa INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
FR2757157B1 (en) * 1996-12-13 1999-12-31 Sanofi Sa INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1999032489A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions

Also Published As

Publication number Publication date
BR0012473B1 (en) 2011-05-03
SK482002A3 (en) 2003-05-02
US6573386B1 (en) 2003-06-03
US20030212278A1 (en) 2003-11-13
CN1149194C (en) 2004-05-12
DE60002472D1 (en) 2003-06-05
HRP20020143A2 (en) 2003-10-31
US6884895B2 (en) 2005-04-26
MXPA01013341A (en) 2002-08-12
EP1200404B1 (en) 2003-05-02
JP2003505371A (en) 2003-02-12
HRP20020143B1 (en) 2010-11-30
EP1200404A2 (en) 2002-05-02
CA2378201C (en) 2007-10-16
ATE238989T1 (en) 2003-05-15
CN1360576A (en) 2002-07-24
HUP9902374A3 (en) 2002-11-28
WO2001005760A3 (en) 2001-07-19
CZ2002147A3 (en) 2003-02-12
AU6308400A (en) 2001-02-05
CA2378201A1 (en) 2001-01-25
DE60002472T2 (en) 2004-02-26
ES2197106T3 (en) 2004-01-01
PL352477A1 (en) 2003-08-25
HU9902374D0 (en) 1999-10-28
PL198521B1 (en) 2008-06-30
BR0012473A (en) 2002-04-02
SK286875B6 (en) 2009-07-06
HUP9902374A2 (en) 2001-05-28

Similar Documents

Publication Publication Date Title
FI89167C (en) FRUIT PROCESSING FLAVONYL-1,4-DIHYDROPYRIDINE DERIVATIVES
SK69695A3 (en) Process for preparing benzofuran compounds
US6706890B2 (en) Method for producing oxindoles
EP1200404B1 (en) Process for the preparation of spiro[(4-cyclohexanone)- [3h] indol-2'[1'h]-one derivatives
SU936813A3 (en) Process for producing derivatives of tetrahydropyridinylindole or their acid salts
Jones Preparation of 2-substituted indole sulfonamides and subsequent conversion to indole-2-carboxylic acids, indole-2-carbonitriles, and 2-acylindoles
JP2682705B2 (en) A method for producing a 2,6-dichlorophenylaminobenzeneacetic acid derivative and a diphenylamine derivative.
US3308134A (en) Spiro(indan-2, 3'-indoline)-1, 2'-diones
AU735516B2 (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
KR20050039749A (en) Process for preparing rizatriptan
KR101752932B1 (en) Intermediates and processes for the preparation of 4-(acetylamino))-3-[(4-chloro-phenyl)thio]-2-methyl-1h-indole-1-acetic acid
EA005034B1 (en) Thio-oxindole derivatives
HUP0201570A2 (en) New process for the preparation of spiro [(4-cyclohexanone)-[3h]indol]-2'[1'h]-one derivatives
US5703233A (en) Quinilone disulfide as intermediates
US4432901A (en) Beta-lactam compounds containing a C-acetal group and process for their preparation
Castro-Castillo et al. Synthesis of a-ring-substituted 5, 6, 8, 12b-tetrahydroisoindolo [1, 2-a] isoquinolin-8-ones
HU211400B (en) Process for producing gramine derivatives
NO300973B1 (en) Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3- [2- (2-methyl-1H-imidazol-1-yl) methyl] -4H-carbazol-4-one
JPS6133023B2 (en)
CH589651A5 (en) Pyrido (2,3-d) pyrimidine-(2,4) (1H, 3-H)-diones - antiinflammatories, analgesics and CNS depressants
HUP0303062A2 (en) New process and new intermediates for preparation of carboxamido-thiazole derivatives
JPH01180884A (en) Novel spiropyrrolidine-2,5-dione derivative and production thereof
MXPA99011973A (en) Process for preparing 4-substituted-1h-indole-3-glyoxamides
HU212967B (en) Process for producing 7-chloro-quinaldine
HU199401B (en) Process for producing n-phenylmalonic acid monoamides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/013341

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/01625/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2378201

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 482002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 008103151

Country of ref document: CN

Ref document number: PV2002-147

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2000949825

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P20020143A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 10030648

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000949825

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-147

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2000949825

Country of ref document: EP